Expressed RNAi for lasting treatment or cure

Tacere Therapeutics develops drugs for human conditions using RNA interference (RNAi) and ddRNAi gene-silencing technology from Benitec Biopharma. This approach, called Expressed RNAi, promises lasting treatment or cure with a single dose.

Our most advanced drug program – TT-034 for Hepatitis C – has commenced Phase l/lla clinical trial, with the first human dosed in May 2014. Our pipeline also includes drugs to treat Age-Related Macular Degeneration

Tacere Therapeutics is a Benitec Biopharma company.

Our biological drugs target and silence unwanted genes, safely and with lasting effect.
More

TT-034, our drug to treat Hepatitis C
with a single dose, has entered human clinical trials. More

 
 
 

Tacere Therapeutics Inc, 4900 Hopyard Rd, Suite 100, Pleasanton CA 94588, USAP. +1 925 858 9299           E. info@tacerebio.com

 
Copyright © Tacere Therapeutics Inc. All rights reserved.                   Home | Contact